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Available online 12 December 2015Background: Many patients from Toroku, Japan, who have chronic arsenic exposure demonstrate whole-body
sensory disturbance that is slightlymore pronounced in the extremities. Although previous research in this pop-
ulation showed amild peripheral neuropathy, it is unknownwhether these patients have central nervous system
impairment. To investigate the lesion sites underlying sensory disturbance related to chronic arsenic poisoning,
we analyzed somatosensory evoked potentials (SEP).
Methods: Clinical features, nerve conduction study results, and median and/or tibial SEP were analyzed in
patients with chronic arsenic exposure (total, 13 patients;median& tibial, 4; median, 5; tibial, 4) retrospectively.
The SEP ﬁndings in patients were compared with those in normal controls.
Results: The median SEP results indicated a conduction delay between the proximal brachial plexus and the pri-
mary sensory cortex, and tibial SEP ﬁndings indicated a delay between the dorsal graymatter of the lumbosacral
cord and the primary sensory cortex.
Conclusion: This is the ﬁrst study to identify an impairment of the central somatosensory pathway in patients
with chronic arsenic exposure. Sensory disturbance in these patients is related not only to peripheral neuropathy
but also to impairment of the central nervous system.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Toroku is a small village in a narrow valley in Miyazaki prefecture,
Japan, and residents' houses are dotted along Toroku River. In the
mid-twentieth century, arsenic was intermittently mined and reﬁned
at the Torokumine; the roasters used at themine's reﬁnery were prim-
itive, lacking dust-collecting systems. Therefore, enormous amounts of
efﬂuent gases containing arsenic trioxide leaked from the roasters and
intermittently covered the entire Toroku valley between 1920 and 1962
[1,2]. About 280 residents were exposed to arsenic via food, water, air,
and skin. Although arsenic concentrations in the environment were not
measured during the mine's operation (1920–1962), they were investi-
gated by Miyazaki prefecture in 1972 [1]. The dust from ceiling boards
of residences near the mine revealed extremely high arsenic content
(200–8000 mg/kg). The average arsenic concentrations in neighboring
soil and in water percolating from the slag were 2760 mg/kg and
180 mg/L, respectively. The mean arsenic concentration in the hair ofspirology, Endocrinology and
sity of Miyazaki, 5200 Kihara,
i).
. This is an open access article underToroku district residents (N = 29) was 1.52 mg/kg [1,3]. No arsenic air
pollution occurred after 1962, but sincemany residentswere still drinking
the water from the polluted Toroku River, arsenic exposure continued
long after 1962.
Some of the exposed individuals developed symptoms of chronic ar-
senic poisoning.Manywhose poisoningwas severe experienced serious
respiratory, cardiovascular and skin diseases, and a large number died
prior to 1962 [1]. However, more than 40 patients are still alive in
2015. Although about 50 years have passed since the mine was last op-
erated, many patients still suffer from superﬁcial and deep whole-body
sensory disturbances of varying severity. These sensory disturbances
were identiﬁed in the 1980s andmost of them did not changemarkedly
thereafter. A previous study [4] reported onlymild axonal degeneration
of peripheral nerves based on nerve conduction studies and sural nerve
biopsies, and the authors speculated that arsenic exposure affected not
only peripheral nerves but also other sensory pathways. Sensory distur-
bance due to peripheral neuropathy usually shows a glove-and-
stocking type distribution. Most patients with sensory disturbance due
to chronic arsenic exposure, however, show a whole-body sensory
disturbance that is slightlymore pronounced in the extremities. Sensory
disturbance of the face or trunk might be a symptom of central nervous
system impairment. In this study we investigated the somatosensorythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tials (SEP) in patients with chronic arsenic exposure.
2. Subjects and methods
This was a retrospective study.
2.1. Subjects
2.1.1. Patients with chronic arsenic exposure
All patientswith chronic arsenic exposure underwent annual Toroku
Medical Examinations (TME) from 1974 to the present. Prior to 1962 all
patients lived within 1000 m of the mine roaster and had begun
exhibiting skin ﬁndings (pigmentation or keratosis) typical of arsenic
poisoning.
In 2012 and 2013, total 36 patients with chronic arsenic exposure
underwent annual TME including neurological examinations. Based on
the their medical records and neurological ﬁndings, 17 patients were ex-
cluded from this study because of diabetes mellitus, alcoholism, cervical
or lumbar spondylosis, brain or spinal infarction, or other neurological
disorders and two were excluded because of having cardiac pacemaker
or the history of gastrectomy. In the remained 17 patients, 12 patients
presented symmetrical sensory disturbances and were proposed to re-
ceive nerve conduction study andmedian SEP. Nine of them agreed to re-
ceive the additional physiological examinations. As same way, in 2014
and 2015, total 35 patients underwent annual TME and 17 of them
were excluded because of their neurological disorders. Eleven out of the
remained 18 patients presented symmetrical sensory disturbances and
nine of them received nerve conduction study and tibial SEP. Four of the
nine patients overlapped with the patients who underwent evaluation
of median SEP. We analyzed these data retrospectively to investigate
the sites of the lesions causing these patients' sensory disturbances. The
blood analyses that had been routinely carried out during annual TME
showed no remarkable abnormalities: the complete blood count and
the levels of albumin, total cholesterol, and cholinesterasewere all within
normal ranges, and all patients were negative for syphilis.
2.1.2. Evaluation of sensory impairment
We evaluated sensory disturbances using a sharp toothpick for pain,
test tubes containing water at 0 °C or 50 °C for temperature, soft tissue
paper for touch, and a 128-Hz tuning fork for vibration.We qualitatively
categorized sensory disturbances using ﬁve grades, as follows: ‘–’ nor-
mal (normal sensation), ‘±’ slight (slightly impaired), ‘+’ mild (im-
paired, with greater than half of normal function), ‘++’ moderate
(impaired, with less than half of normal function), and ‘+++’ severe
(sensation almost disappeared). At least two neurologists blind to SEP
results evaluated the sensory impairment of the bilateral forearms and
legs using these tools and qualitatively determined the severity.
2.1.3. Exclusion by nerve conduction study
Nerve conduction studies of the rightmedian, tibial, and sural nerves
were performed in all above selected patients (N = 14). Most patients
showed normal studies, but one individual demonstrated abnormally
low-amplitude sensory nerve action potentials of the right sural nerve
(below 4 μV) andwas excluded from this study. SEP data of the remain-
ing 13 patients (AS group) were analyzed (total, 13 patients; median &
tibial, 4; median, 5; tibial, 4).
2.1.4. Normal controls for SEP
Toobtain normal control values for SEP parameters, we established a
control group consisting of 19 healthy volunteers ranging in age from
the 60s to 80s (NL group; 10 for median SEP and 9 for tibial SEP).
Based on the results of past SEP studies [5,6] and our hypothetical esti-
mation that central conduction time is delayed by 15% in the arsenic
group, theminimum sample size is at least eight in each group. Howev-
er, there is no evidence in past studies supporting this 15% delay, sincethere have been no SEP studies in patients with arsenic exposure. We
therefore recruited normal healthy volunteers in numbers equal to or
greater than the arsenic group for both tibial and median SEP, until
each normal group was age- and height-matched with the respective
arsenic group. Healthy volunteers did not exhibit any neurological
disorders. Written informed consent was obtained from all healthy
volunteers.
This study protocol was approved by the Ethics Committee of the
University of Miyazaki, with a waiver of written informed consent
from patients with chronic arsenic exposure, and was carried out in
accordance with the Declaration of Helsinki.
2.2. Somatosensory evoked potentials
Median and tibial SEP were recorded in nine and eight of the 13 pa-
tients, respectively. In the median SEP examination, the right median
nerve was stimulated at the wrist with a repetition rate of 3 Hz. The
onset latencies of N9 (recorded at the ipsilateral Erb's point (EPi) and
referenced to the contralateral Erb's point (EPc); a component of the
proximal brachial plexus) and N20 (C3’ (2 cm posterior to the C3 place-
ment on the International 10–20 System)— Fz; primary somatosensory
cortex) were analyzed according to previous papers (Fig. 1) [5,7,8].
In the tibial SEP examination, the right tibial nervewas stimulated at
the ankle with a repetition rate of 2 Hz. We analyzed the peak latencies
of P15 (contralateral iliac crest (ICc) — ipsilateral greater trochanter
(GTi); junctional potential of greater sciatic foramen) and N21 (the
ﬁrst lumbar spinous process (L1) — GTi; post-synaptic potential in the
dorsal graymatter of the lumbosacral cord), as well as the onset latency
of P38 (Cz’ (2 cmposterior to Cz)— C3’; primary somatosensory cortex),
in accordance with previous papers (Fig. 1) [6,7,9]. The stimulus
strength was ﬁxed at about 1.2 times the motor threshold. Potentials
were ampliﬁed by ﬁlters set at 1 and1500Hz, and at least 500 responses
were averaged. To ensure the reproducibility of our results, we recorded
SEPs at least twice.
There is controversy over whether latency measurements should
utilize the onsets or peaks of SEP components. Several investigators
have stressed the importance of using the onsets of these components
because they are more relevant to physiological parameters such as
the spinal entry time and the cortical arrival time [10–12]. Furthermore,
for median SEPs, the onsets of the components were more stable than
the peaks [5,12]. For tibial SEPs, a past study [6] tried to establish stan-
dard values and recommended that investigators employ the latencies
of the P15 peak, N21 peak, and P38 onset for two reasons. First, the on-
sets of small components were difﬁcult to deﬁne, and second, the P38
onset indicates the cortical arrival time and would more accurately re-
ﬂect true conduction time than the P38 peak. For the reasons described
above, in this study we employed the onsets of N9 and N20 for median
SEPs and the P15 peak, N21 peak, and P38 onset for tibial SEPs.
2.3. Data analysis
Differences in SEP parameters between AS and NL groupswere eval-
uated using theMann–Whitney U test. No correlation formultiple com-
parisonswere not performed. The statistical signiﬁcance level was set at
P= 0.05. SPSS version 22 software was used for statistical analysis.
3. Results
3.1. Clinical features
The clinical features of patients with chronic arsenic exposure are
summarized in Table 1. They were exposed to arsenic between the
ages of 0 and 37 years, and the duration of exposure ranged from 8 to
37 years. Their neurological ﬁndings showed mainly sensory distur-
bances with only slight motor symptoms. Their sensory disturbances
were distributed throughout the entire body, with a slightly greater
Fig. 1.Waveforms of median (A) and tibial (B) SEP (Case 4 in Table 1). (A) Median SEP: onset latencies of N9 and N20were measured. (B) Tibial SEPs: peak latencies of P15 and N21 and
onset latency of P38 were measured. EPi, ipsilateral (right) Erb's point; EPc, contralateral (left) Erb's point; C3’, 2 cm posterior to C3 placement on the International 10-20 System; ICc,
contralateral iliac crest; Gti, ipsilateral greater trochanter; L1, spinous process of the ﬁrst lumbar vertebra; Cz’, 2 cm posterior to Cz.
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system were observed.
3.2. SEP ﬁndings
Table 2 summarizes the SEPﬁndings for the AS andNL groups.Median
SEP results showed no signiﬁcant differences between the two groups in
the latency of N9 onset, but the central sensory conduction time between
the N9 and N20 onsets was longer in the AS group than in the NL group.
Tibial SEP results demonstrated no signiﬁcant differences between the
AS and NL groups in the latency of the P15 peak or the inter-peak latency
between P15 and N21, but the central sensory conduction time between
the N21 peak and P38 onset was signiﬁcantly longer in the AS group.
4. Discussion
Wereport twomainﬁndings. First,median SEPﬁndings showeda lon-
ger conduction time between theN9 andN20 onsets in the AS group than
in the NL group. Second, tibial SEP ﬁndings demonstrated a longer con-
duction time between the N21 peak and P38 onset in the AS group than
the NL group. Median SEP reﬂects the conduction delay between the
proximal brachial plexus and the primary sensory cortex, while tibial
SEP indicates the delay between the dorsal graymatter of the lumbosacral
cord and the primary sensory cortex. Based on our overall ﬁndings, we
conclude that chronic arsenic exposure caused central nervous system
impairment from the spine to the sensory cortex.Table 1
Clinical features of patients.
Case
no.
Age Arsenic exposurea
(years old)
Motor Sensory imp
Weakness DTR Pain
1 70s 0–15 − Slightly↓ +++
2 80s 21–29 − Slightly↓ +++
3 80s 0–31 − Normal +
4 70s 15–27 − Normal ++
5 80s 0–37 ± Normal +++
6 80s 0–22 − Normal +++
7 80s 0–31 − Normal ++
8 70s 0–23 − Normal +++
9 70s 0–18 − Normal ++
10 60s 0–15 − Normal +++
11 70s 0–27 − Normal ++
12 60s 0–20 − Normal ++
13 70s 0–19 − Normal +
–, No symptom; ±, slight; +, mild; ++, moderate; +++, severe.
a Arsenic exposure, age of patients during which they lived within 1000 m of the mine roas4.1. Peripheral neuropathy and chronic arsenic exposure
The ﬁrst neurological symptoms caused by arsenic were mainly
peripheral neuropathies due to inhalation or ingestion [13]. In the
present study, however, only one of 14 patients with chronic arsenic
exposure experienced peripheral neuropathy. In previous studies,
various degrees of symmetric sensory symptoms, such as numbness
and paresthesias of the distal extremities, were accompanied by slight
or mild motor weakness [2,14]. A study of 156 patients with chronic ar-
senic exposure due to drinking arsenic-contaminated water
(0.05–3.2 mg/L) inWest Bengal, India, indicated that 74 of 156 patients
(47%) had paresthesias and only one-third of the patients with pares-
thesias had abnormal nerve conduction studies [15]. An electrophysio-
logical study from Inner Mongolia Autonomous Region indicated that
chronic ingestion of arsenic in drinking water (0.158 mg/L) did not af-
fect motor or sensory nerve conduction studies [16]. Chronic arsenic
exposure leads to abnormal nerve conduction studies in only a fraction
of patients with sensory symptoms.
4.2. Central nervous system impairment and chronic arsenic exposure
The effects of chronic arsenic exposure on the central nervous
system remain unclear. Several studies reported encephalopathy as
well as impairment of high-level cognitive functions such as learning,
recent memory, and concentration in patients with chronic arsenic
exposure [14]. However, neurophysiological studies of the effects ofairment Romberg sign SEP
Temperature Touch Vibration
+++ +++ +++ ± Median & tibial
+++ +++ ++ − median & tibial
+ + + − median & tibial
++ ++ ++ − Median & tibial
+++ +++ ++ ± Median
+++ ++ ++ − Median
++ + + − median
+++ ++ ++ − Median
++ ++ ++ − Median
+++ + + − Tibial
++ ++ ++ ± Tibial
++ + + − Tibial
+ ± ± − Tibial
ter prior to 1962.
Table 2
SEP parameters of arsenic-exposed patients and normal subjects.
AS NL Mann Whitney test
P value
Mean SD Mean SD
Median nerve SEP
Sex (M/F) 3M/6F 4M/6F
Age (year) 79.6 3.9 79.6 5.8 0.842
Body height (m) 1.51 0.09 1.55 0.06 0.315
SEP parameters (ms)
N9 onset 7.75 0.67 7.84 0.38 0.842
N9 onset–N20 onset 8.46 0.54 7.78 0.63 0.028*
Tibial nerve SEP
Sex (M/F) 5M/3F 6M/3F
Age (year) 73.9 7.1 72.5 9.6 0.696
Body height (m) 1.56 0.06 1.57 0.10 0.633
SEP parameters (ms)
P15 peak 15.29 1.36 15.26 0.88 0.762
P15 peak–N21 peak 6.51 0.63 6.19 0.87 0.360
N21 peak–P38 onset 15.03 1.79 12.17 2.31 0.027*
AS, patients with chronic arsenic exposure; NL, normal subjects.
Bold data indicates P values less than 0.05
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few institutes. A brainstem auditory evoked potential study from
Thailand showed no abnormalities in patients with chronic arsenic ex-
posure [17]. Electroencephalography and visual evoked potential re-
cordings were performed in patients with chronic arsenic exposure in
Poland (mean urine arsenic concentration, 0.0119mg/L) [18]. Although
the electroencephalographic ﬁndings in these patients were not signif-
icantly different from those of normal controls, the latencies of visual
evoked potentials were longer in patients than in controls; however, it
is unclear which anatomic site between the retina and visual cortex
was responsible for these delayed latencies. In a study in rats [19],
multimodal evoked potentials did not signiﬁcantly vary with the dose
or time of arsenic exposure. The present paper, using SEP methodology,
is the ﬁrst to demonstrate a central conduction time delay caused by
chronic arsenic exposure. It is noteworthy that the central nervous im-
pairment was present even though nearly 50 years had passed since
the patients' arsenic exposure.
4.3. Mechanisms of central nervous system impairment caused by chronic
arsenic exposure
The mechanisms through which arsenic impairs the central nervous
system are still unclear, but two possible hypotheses are suggested.
First, arsenic exposure can induce atherosclerosis by increasing platelet
aggregation and reducing ﬁbrinolysis [20], and this atherosclerosis has
been related to cardio- and cerebrovascular dysfunction [21,22]. Sub-
clinical ischemic lesions might occur in the central nervous system
and cause prolonged central sensory conduction times. Second, arsenic
trioxidemetabolites were reported to penetrate the blood–brain barrier
in patients with leukemia [23], and in an animal study, arsenic trioxide
had toxic effects onmicroglial cells [24]. Microglial cell deathmight lead
to slowed central sensory conduction in patients.
4.4. Limitations
We evaluated the sensory pathway from peripheral nerves to the
primary sensory cortex, but did not investigate sensory-related cortical
areas (e.g., the secondary sensory cortex). Nerve conduction and SEP
studies might not be sufﬁcient to identify the lesion sites responsible
for patients' sensory disturbances.
5. Conclusions
This is theﬁrst study to identify impairment of the central somatosen-
sory pathway in patients with chronic arsenic exposure. It is noteworthythat this impairment has persisted even though almost 50 years has
passed since the patients' last arsenic exposure. Patients' sensory distur-
banceswere related not only to peripheral neuropathy but also to impair-
ment of the central nervous system.Conﬂict of interest
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